Form 6-K ObsEva SA For: May 18
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of May 2022
Commission File Number: 001-37993
(Translation of registrants name into English)
Chemin des Aulx, 12
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: ☒ Form 20-F ☐ Form 40-F
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
INCORPORATION BY REFERENCE
This Report on Form 6-K shall be deemed to be incorporated by reference into the registration statements on Form F-3, as amended (No. 333-221462, 333-233069, 333-260974 and 333-262820) of ObsEva SA (including any prospectuses forming a part of such registration statements) and the registration statements on Form S-8 (Registration No. 333-216170, 333-231629, 333-249457 and 333-263234) of ObsEva SA and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.
|99.1||Press Release dated May 19, 2022.|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|Date: May 19, 2022||By:|
|Name Brian OCallaghan|
|Title: Chief Executive Officer|
ObsEva SA Announces that Shareholders Approved all Board Proposals at its
2022 Annual General Meeting held on May 18, 2022
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange
Geneva, Switzerland May 19, 2022 ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for womens health, today announced that shareholders approved all Board proposals at its 2022 Annual General Meeting held on May 18, 2022.
The approved items are as follows:
Shareholders approved the Annual Report, the Statutory Financial Statements and the Consolidated Financial Statements for Fiscal Year 2021
Shareholders granted discharge to the Members of the Board of Directors and to the Executive Committee for year 2021
Shareholders approved the proposed appropriation of the Financial Results for year 2021
Shareholders approved the proposed elections to the Board of Directors and election of the Chairperson of the Board of Directors
Shareholders approved the proposed elections to the Compensation Committee
Shareholders approved the re-election of PricewaterhouseCoopers SA as ObsEva SAs Auditors and Independent Registered Public Accounting Firm
Shareholders approved the re-election of Perréard de Boccard SA as Independent Representative
Shareholders approved the proposed compensation of the Board of Directors and the Executive Committee
Shareholders approved the proposed increase of ObsEva SAs Authorized Share Capital
Shareholders approved the proposed increase of ObsEva SAs Conditional Share Capital for Financing Purposes
Shareholders approved the proposed increase of ObsEva SAs Conditional Share Capital for Equity Plans
Shareholders approved the proposed change to ObsEva SAs Equity Incentive Plan
Shareholders approved the Issuance of Conversion Shares and Warrant Shares under Securities Purchase Agreement
For a detailed agenda, including items submitted to shareholders vote and related proposals of the Board of Directors, please refer to the full invitation, which may be found in the Investors / General Meetings section of the companys website www.ObsEva.com.
To access the general meetings section of the Companys website, please click here.
To access the AGM 2022 section of the general meetings section directly, please click here.
To access the full invitation to the AGM 2022 directly, please click here.
ObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve womens health. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on new therapies for the treatment of uterine fibroids, endometriosis, and preterm labor. ObsEva is listed on the Nasdaq Global Select Market and is traded under the ticker symbol OBSV and on the SIX Swiss Exchange where it is traded under the ticker symbol OBSN. For more information, please visit www.ObsEva.com.
For further information, please contact:
CEO Office Contact:
+41 22 552 1550
+1 (917) 969-3438
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Fireweed Provides Update on Name Change to ‘Fireweed Metals Corp.’
- Correction - Jowell Global Ltd. Announces First Quarter 2022 Unaudited Financial Results
- Chemesis International Inc. Announces Share Consolidation
Create E-mail Alert Related CategoriesSEC Filings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!